UBS Group AG - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$2,434,457
-7.3%
81,858
-43.8%
0.00%0.0%
Q2 2023$2,625,387
+176.3%
145,693
+146.2%
0.00%
Q1 2023$950,238
-35.7%
59,168
-26.7%
0.00%
-100.0%
Q4 2022$1,476,700
+822.9%
80,694
+891.4%
0.00%
Q3 2022$160,000
-55.3%
8,139
-57.6%
0.00%
Q2 2022$358,000
-76.2%
19,180
-72.0%
0.00%
-100.0%
Q1 2022$1,504,000
+0.3%
68,493
+29.7%
0.00%
Q4 2021$1,500,000
+235.6%
52,820
+148.8%
0.00%
Q3 2021$447,000
+609.5%
21,227
+414.1%
0.00%
Q1 2021$63,000
+110.0%
4,129
+96.7%
0.00%
Q4 2020$30,000
-81.1%
2,099
-76.9%
0.00%
Q2 2020$159,000
+31.4%
9,093
+10.7%
0.00%
Q1 2020$121,000
-71.8%
8,216
-51.9%
0.00%
Q4 2019$429,000
+210.9%
17,087
+85.7%
0.00%
Q3 2019$138,000
+711.8%
9,199
+1242.9%
0.00%
Q2 2019$17,000
-98.3%
685
-98.4%
0.00%
Q1 2019$988,000
+5388.9%
43,416
+7196.8%
0.00%
Q4 2018$18,000
-61.7%
595
-63.7%
0.00%
Q3 2018$47,0001,6370.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders